CD-38 Immunohistochemistry at Test Zone Diagnostic Center

Understanding CD-38 Immunohistochemistry at Test Zone Diagnostic Center

CD-38 Immunohistochemistry at Test Zone Diagnostic Center is a highly specialized, state-of-the-art pathology investigation used to detect and analyze the expression of the CD38 glycoprotein on the surface of cells. CD38, also known as cluster of differentiation 38, is a transmembrane glycoprotein that plays a critical role in cell adhesion, signal transduction, and calcium signaling. This protein is expressed at variable levels on various hematological cells, including T-cells, B-cells, natural killer (NK) cells, and dendritic cells. Most importantly, CD38 is highly and consistently expressed on plasma cells, making it an invaluable diagnostic, prognostic, and therapeutic marker in hematopathology.

The primary clinical utility of CD-38 Immunohistochemistry (IHC) lies in the evaluation of plasma cell dyscrasias, most notably multiple myeloma, and certain lymphoproliferative disorders such as chronic lymphocytic leukemia (CLL). At Test Zone Diagnostic Center, this advanced laboratory technique is performed on tissue specimens, such as bone marrow trephine biopsies, lymph node biopsies, or other tissue masses, to assist clinical oncologists and hematologists in establishing precise diagnoses. By utilizing highly specific monoclonal antibodies targeted against the CD38 antigen, our expert pathologists can visualize the distribution, density, and localization of plasma cells and other lymphoid subsets under a high-resolution light microscope.

The diagnostic value of CD-38 IHC extends beyond simple cell identification. It serves as a vital prognostic indicator in chronic lymphocytic leukemia, where high CD38 expression on B-cells correlates with a more aggressive clinical course and shorter survival times. Furthermore, with the advent of targeted immunotherapies, such as anti-CD38 monoclonal antibodies (e.g., daratumumab), determining CD38 expression status has become essential for selecting patients who are candidates for these highly effective biological therapies. Test Zone Diagnostic Center utilizes advanced automated staining platforms and rigorous quality control protocols to ensure that every CD-38 IHC slide is processed with maximum sensitivity and specificity, providing clinicians with reliable, actionable results.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-38 Immunohistochemistry is a laboratory test performed on tissue specimens, patient preparation depends entirely on the procedure used to obtain the tissue sample. The test itself does not require any direct preparation from the patient, as it is performed on a biopsy specimen that has already been collected. However, patients undergoing the primary biopsy procedure (such as a bone marrow biopsy or lymph node biopsy) must follow specific clinical guidelines:

• Fasting Requirements: If the biopsy is to be performed under conscious sedation or general anesthesia, patients are typically instructed to fast (nil by mouth) for 6 to 8 hours prior to the procedure.
• Medication Management: Patients must inform their physician of all ongoing medications, particularly anticoagulants (blood thinners) such as aspirin, clopidogrel, warfarin, or direct oral anticoagulants (DOACs). These medications may need to be temporarily discontinued under medical supervision to minimize the risk of bleeding during the biopsy.
• Medical History Disclosure: It is essential to disclose any history of bleeding disorders, allergies to local anesthetics, or active infections at the planned biopsy site.
• Post-Procedure Care: Patients should arrange for a family member or friend to drive them home if sedation is administered during the biopsy collection.

During the Procedure

The laboratory phase of CD-38 Immunohistochemistry at Test Zone Diagnostic Center is a multi-step, highly controlled process executed by skilled histotechnologists and evaluated by consultant pathologists. The procedure involves the following clinical and technical steps:

• Specimen Collection and Fixation: The tissue specimen (e.g., bone marrow biopsy or lymph node) is collected by a clinician and immediately placed in a fixative solution, typically 10% neutral buffered formalin, to preserve cellular structure and prevent autolysis.
• Tissue Processing and Embedding: The fixed tissue is processed through a series of graded alcohols and xylene, and then embedded in paraffin wax to form a solid block (formalin-fixed paraffin-embedded or FFPE block).
• Microtomy: Ultra-thin sections of the tissue, measuring approximately 3 to 4 micrometers, are cut using a precision microtome and mounted onto specialized, positively charged glass slides.
• Deparaffinization and Rehydration: The tissue sections are heated and treated with xylene to remove the paraffin wax, followed by rehydration through descending grades of alcohol to water.
• Antigen Retrieval: To expose the CD38 epitopes that may have been masked during formalin fixation, the slides undergo heat-induced epitope retrieval (HIER) using specific buffer solutions in a temperature-controlled water bath or automated stainer.
• Antibody Incubation: The slides are incubated with a highly specific primary monoclonal antibody directed against the CD38 antigen. After washing away unbound primary antibodies, a secondary detection system (typically a polymer-based horseradish peroxidase system) is applied.
• Chromogen Visualization: A chromogenic substrate, such as diaminobenzidine (DAB), is applied to the slide. The enzyme reaction produces a visible, insoluble brown precipitate at the site of CD38 antigen-antibody binding.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to visualize cell nuclei, dehydrated, cleared, and mounted with a coverslip for microscopic examination.

When is a CD-38 Immunohistochemistry Performed?

Diagnosis of Multiple Myeloma and Plasma Cell Neoplasms

Multiple myeloma is a hematological malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow. Because CD38 is highly and uniformly expressed on both normal and neoplastic plasma cells, CD-38 Immunohistochemistry is routinely performed on bone marrow trephine biopsies to identify, quantify, and characterize the plasma cell infiltrate. It helps pathologists distinguish between a normal, sparse distribution of plasma cells and a dense, sheet-like infiltration characteristic of multiple myeloma, plasma cell leukemia, or solitary plasmacytoma.

Prognostic Stratification in Chronic Lymphocytic Leukemia (CLL)

In patients diagnosed with chronic lymphocytic leukemia, CD-38 expression on the leukemic B-cells serves as an important independent prognostic marker. Pathologists perform CD-38 IHC or flow cytometry to determine the percentage of CLL cells expressing CD38. A threshold of 30% or greater is widely accepted as a marker of poor prognosis, indicating a more rapid disease progression, shorter treatment-free survival, and resistance to conventional chemotherapy regimens, thereby guiding clinicians toward more aggressive or targeted therapeutic strategies.

Evaluation of Lymphoproliferative Disorders and Lymphomas

CD-38 Immunohistochemistry is frequently utilized in the diagnostic workup of various non-Hodgkin lymphomas, particularly those with plasmacytoid differentiation or those arising from post-germinal center B-cells. This includes lymphoplasmacytic lymphoma (associated with Waldenström macroglobulinemia), diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma, where CD38 expression patterns help refine the histological classification and differentiate these malignancies from other reactive or neoplastic lymphoid proliferations.

Monitoring Response to Anti-CD38 Targeted Therapies

With the clinical integration of monoclonal antibodies targeting CD38, such as daratumumab and isatuximab, CD-38 IHC has become a critical tool for therapeutic monitoring. Clinicians request this test to confirm the presence of the target antigen prior to initiating therapy and to evaluate bone marrow biopsies post-treatment. This assessment helps determine therapeutic efficacy, detect minimal residual disease (MRD), and identify potential antigen escape or down-regulation that may signal the development of treatment resistance.

Differentiation of Reactive vs. Neoplastic Plasma Cell Infiltrates

In many inflammatory, infectious, or autoimmune conditions, tissue biopsies may show a prominent infiltration of plasma cells, mimicking a plasma cell neoplasm. CD-38 Immunohistochemistry, when combined with kappa and lambda light chain immunohistochemistry, allows pathologists to evaluate the clonality of the CD38-positive plasma cells. A balanced expression of kappa and lambda indicates a benign, reactive process, whereas a restricted expression of a single light chain (monoclonality) confirms a neoplastic process, such as multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS).

What Does a CD-38 Immunohistochemistry Detect?

CD-38 Immunohistochemistry is designed to detect specific cellular and pathological features within tissue specimens. The key findings and parameters evaluated during this microscopic analysis include:

• Presence of CD38-positive plasma cells in the bone marrow or lymphoid tissues.
• Percentage of plasma cells relative to the total nucleated cell population.
• Spatial distribution of CD38-positive cells (e.g., interstitial, clustered, or sheet-like patterns).
• Intensity of CD38 staining on the cell membrane (graded as weak, moderate, or strong).
• Expression of CD38 on mature and immature B-lymphocytes.
• Co-expression of CD38 on neoplastic B-cells in chronic lymphocytic leukemia.
• Presence of CD38-positive plasma cells in extra-medullary tissues (plasmacytomas).
• Atypical cytological features of CD38-positive cells, such as multinucleation or prominent nucleoli.
• Proportion of CD38-positive cells in lymph node germinal centers.
• Expression of CD38 on activated T-lymphocytes and natural killer (NK) cells.
• Infiltration of CD38-positive cells in inflammatory lesions or autoimmune tissue damage.
• Reduction or loss of CD38 expression following targeted anti-CD38 therapy.
• Localization of CD38-positive cells within specific microenvironmental niches.
• Association of CD38 expression with other diagnostic markers like CD138, CD56, and CD19.
• Clonal restriction when analyzed alongside kappa and lambda light chains.
• Presence of CD38-positive hematological precursors in bone marrow specimens.
• Abnormal localization of immature plasma cells (plasmablasts).
• Density of CD38-positive cells in mucosal biopsies (e.g., gastrointestinal tract).
• Expression of CD38 in non-hematopoietic tumors (rare but clinically relevant).
• Clear demarcation of tumor margins in localized plasmacytomas.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that timely and accurate pathology reports are critical for effective clinical decision-making, particularly in oncology and hematology. The turnaround time for CD-38 Immunohistochemistry typically ranges from 3 to 5 working days. This timeframe is necessary to ensure meticulous tissue processing, precise antigen retrieval, optimal antibody incubation, and comprehensive microscopic evaluation by our consultant pathologists. In complex cases requiring additional stains or clinical correlation, the reporting time may be slightly extended to guarantee diagnostic accuracy.

Patients and referring physicians can easily access diagnostic reports through multiple convenient channels. Test Zone Diagnostic Center provides an advanced online reporting portal accessible via our official website. Once the report is finalized and signed off by the reporting pathologist, an automated SMS notification containing a secure download link is sent to the patient’s registered mobile number. Physical copies of the reports, complete with high-resolution microscopic images where applicable, can also be collected directly from our main diagnostic center or designated collection points.

CD-38 Immunohistochemistry Findings Overview

The following table outlines the typical parameters evaluated during CD-38 Immunohistochemistry, comparing normal physiological findings with possible pathological abnormalities:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Bone Marrow Plasma Cells	Scattered, representing <5% of total nucleated cells.	Sheet-like clusters, representing >10% to 90% of cells (Multiple Myeloma).
Staining Intensity	Moderate to strong, uniform membranous staining.	Variable, weak, or completely absent staining in treated or mutated clones.
CLL B-Lymphocytes	<30% of B-cells expressing CD38.	>30% of B-cells expressing CD38 (Poor prognostic indicator).
Lymph Node Architecture	CD38 expression confined to germinal centers and plasma cells.	Diffuse, uncontrolled infiltration of CD38-positive cells disrupting architecture.
Cellular Distribution	Interstitial, isolated, or small clusters of plasma cells.	Large, cohesive aggregates, nodular clusters, or diffuse sheets of cells.
Cell Morphology	Mature plasma cells with eccentric nuclei and abundant cytoplasm.	Atypical, pleomorphic, multinucleated, or plasmablastic morphology.
Clonality (with Kappa/Lambda)	Polyclonal (mixed kappa and lambda expression).	Monoclonal (restricted expression of either kappa or lambda light chain).
Extra-medullary Tissue	Absence of abnormal CD38-positive plasma cell infiltrates.	Dense localized collection of CD38-positive cells (Plasmacytoma).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for CD-38 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with extensive experience in hematopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate care throughout the diagnostic journey.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to strict national and international laboratory quality standards to ensure highly reproducible results.
• Professional Reporting: Our reports are detailed, comprehensive, and structured to provide clear, actionable insights for referring oncologists.
• Modern Diagnostic Approach: We utilize state-of-the-art automated immunohistochemistry platforms that minimize human error and optimize staining quality.
• Comfortable Environment: Our diagnostic facilities are designed to provide a clean, safe, and comfortable experience for all patients during sample collection.
• Convenient Location: Easily accessible main center and collection points across the region facilitate hassle-free specimen submission and report collection.
• Commitment to Accurate Diagnosis: We employ rigorous internal and external quality control assessments to maintain the highest level of diagnostic precision.